Instrument Inactif

Autres langues Tiger X Medical Inc Other OTC

Actions

US88677A1043

Cours en clôture Other OTC Autres places de cotation
- ^USD	-

14/05	Transcript : BioCardia, Inc., Q1 2024 Earnings Call, May 14, 2024
01/05	BioCardia, Inc. annonce les résultats du critère d'évaluation primaire de la cohorte ouverte de l'essai de thérapie cellulaire CardiAMP dans l'ischémie myocardique chronique	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

BioCardia : Reports First Quarter 2024 Business Highlights and Financial Results	14/05
BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024	09/05
BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes	01/05
BioCardia, Inc. Announces the Primary Endpoint Results of the Open Label Roll-In Cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial	01/05
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort	25/04
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort	25/04
BioCardia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
BioCardia : Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results	27/03
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024	20/03
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership	13/03
BioCardia, Inc. and StemCardia, Inc. Announce Long-Term Partnership to Advance StemCardia?s Investigational Pluripotent Stem Cell Product Candidate for Treatment of Heart Failure	13/03
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study	12/03
BioCardiaAnnounces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study	12/03
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure	04/03
Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure	04/03
BioCardia, Inc. announced that it expects to receive $0.874999 million in funding	09/02
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA	08/02
BioCardia, Inc. Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA	08/02
BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference	31/01
BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders	03/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Tiger X Medical Inc Other OTC

Actions

US88677A1043

Autres langues

Filtres